LNP formulation

RiboPro provides custom LNP formulation services for research and therapeutic applications.

Whether your RNA is manufactured by RiboPro or supplied externally, we can formulate it using customer-provided lipids or our proprietary lipid platform developed for efficient delivery and low toxicity

 

Request LNP formulation
  • High mRNA delivery efficiency
  • Low toxicity and immunogenicity
  • Expanded control over bio-distribution

Custom LNP formulation

RiboPro provides custom lipid nanoparticle (LNP) formulation services for mRNA and other RNA-based therapeutics. We can formulate both RiboPro-produced RNA and customer-supplied RNA using either customer-provided lipids or our proprietary lipid systems.

Our LNP platform combines proprietary ionizable and core lipid technologies with an in-house developed microfluidic formulation process. The result is highly reproducible LNP formulations designed to achieve efficient RNA delivery while maintaining low toxicity and low immunogenicity.

A key differentiator of our platform is the use of a proprietary core lipid that demonstrates reduced liver biodistribution compared with conventional cholesterol-based formulations, creating opportunities for delivery beyond the liver. Combined with efficient endosomal escape, our LNPs are well suited for advanced research and therapeutic development applications.

Typical formulation characteristics:

Parameter Typical Value
Particle size 50-200 nm
PDI < 0.2
Encapsulation Efficiency > 85%
RNA concentration 0.01-0.5 mg/mL

 

Our services include:

  1. Buffer exchange and formulation optimization
  2. Dilution or concentration to application-specific RNA concentrations
  3. Quality control by Dynamic Light Scattering (DLS), including particle size and PDI
  4.  Frozen shipment on dry ice (standard) or blue-ice shipment, depending on storage requirements and shipment destination. We offer worldwide shipping.

Tailor your formulation

Every RNA program has unique delivery requirements. Our formulation services can be tailored to your application, target tissue, analytical requirements, and downstream development goals.

Customization Option Available Options
Formulation Standard and proprietary LNP formulations tailored to your application.
Target delivery  Co-development of targeted LNP systems using our proprietary lipid technologies.
Buffer Standard buffer: TBS + 10% sucrose, optimized for frozen storage and transport. Alternative buffer systems available upon request.
Sterile filtering 0.22 μm
0.45 μm
QC assays Particle size and PDI by DLS
Zeta potential
RNA encapsulation by RiboGreen
Apparent pKa by TNS (upon request)

Functional mRNA delivery with RiboPro LNPs

RiboPro LNPs delivered eGFP-encoding mRNA to cultured cells, resulting in strong and widespread reporter expression. Under the tested in vitro conditions, RiboPro LNPs produced cellular eGFP fluorescence within the range of the benchmark LNP and a higher average signal than the third-party formulation.

Fluorescence microscopy confirms eGFP expression across the cell population, demonstrating that the delivered mRNA remained functional and was successfully translated by the cells.

Cells were imaged and analyzed 24 hours after treatment. Cellular eGFP fluorescence was quantified using corrected total cellular fluorescence (CTCF). Representative fluorescence, brightfield and merged microscopy images are shown at low and high magnification. Scale bars represent 50 µm.

Demonstrated Applications

Cancer Immunotherapy

RiboPro LNPs have been used for delivery of mRNA cancer vaccine candidates designed to enhance antigen-specific T-cell responses. In preclinical studies, LNP-formulated mRNA constructs generated strong IFNγ responses and were associated with reduced tumour growth.

The data illustrate an example of the delivery of HPV E7-OligoDOM™ mRNA using the RiboPro LNP platform. In a prophylactic TC-1 tumour model, mice were immunized prior to tumour challenge (A). Analysis of splenocytes showed strong antigen-specific IFNγ responses following vaccination, indicating effective activation of T cells against the tumour-associated antigen (B). Importantly, these enhanced immune responses translated into reduced tumour growth compared with control groups, with complete tumour growth suppression observed in the 2 µg HPV E7-OligoDOM™ treatment group (C).

These results demonstrate the ability of the RiboPro LNP platform to efficiently deliver mRNA cancer vaccine candidates and support the generation of potent anti-tumour immune responses.

Further details on the experimental setup and results can be found in the full study.

Ready to discuss your LNP project?

Fill out the form below and get your personalized quote today. If you prefer, you can also schedule a meeting with one of our Product Specialists. We’re excited to work with you!

"*" indicates required fields

Privacy statement*

Welcome on our new website

Please bear with us while we get everything in order.
Importantly, we are ready to receive your order, quote request or meeting request as per usual.
We look forward helping you with the highest quality mRNA.